Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SADDRIN-1 neoadjuvant DDR inhibition in non-metastatic soft tissue sarcoma
NL-OMON60212Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in soft tissue sarcoma (STS), sponsored by Netherlands Cancer Institute. Primary endpoint: Primary endpoint(s). Started Jan 2022; status: completed.
02
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON60212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60212.